STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G/A

OKUR Schedule 13G/A filing by Citadel Advisors

Citadel Advisors reported beneficial ownership of 223.1K shares, representing 1.7% of OnKure Therapeutics, Inc. in this filing.

FiledFeb 17, 2026
Ownership dateDec 31, 2025
Reported shares223.1K
Reported ownership1.7%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 0
Shared voting power 223.1K
Sole dispositive power 0
Shared dispositive power 223.1K
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$2.40as of Feb 17, 2026
Latest tracked price$4.15as of Aug 6, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
Citadel Advisors
CIK
CIK0001423053
Accession
0001104659-26-016541
Form
Schedule 13G/A
Open SEC filing View OKUR ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →